chronic nephropathy

chronic nephropathy

a kidney disorder characterized by generalized or local damage to the tubulointerstitial areas of the kidney. The condition frequently results from more than a single cause, such as diabetes and a bacterial infection. Toxins, in the form of drugs or heavy metals, including cadmium or lead, are common causes, as are gout, cystinosis, and other metabolic disorders. Sickle cell disease is one of several inherited factors that may contribute to chronic nephropathy, but the condition can also develop from no known cause. Symptoms include polyuria, renal acidosis, edema, proteinuria, and blood in the urine. Treatment varies with correction of underlying causal factors. See also kidney disease.
References in periodicals archive ?
Ochratoxin A and human chronic nephropathy in Tunisia: is the situation endemic?
Melioidosis occurs mainly in patients with underlying diseases such as diabetes (37%-60% of cases), chronic alcoholism (12%-39%), thalassemia, and chronic nephropathy, and in persons receiving long-term corticosteroid treatment (7).
Lead was confirmed as the cause when the bone lead content of these patients with cryptogenic kidney disease was found to be significantly greater than in other patients with chronic nephropathy of recognized cause.
Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial.
Using its novel approach, Promedior is initially developing a pipeline of drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration and diabetic retinopathy (eye); pulmonary fibrosis, scleroderma and COPD (lung); and acute and chronic nephropathy (kidney).
PRM-151 has shown broad anti-fibrotic and anti-inflammatory activity in multiple preclinical models of fibrotic disease and inflammation, including pulmonary fibrosis, acute and chronic nephropathy, glaucoma, age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
Utilizing this novel approach, Promedior is initially developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, and diabetic retinopathy (eye); pulmonary fibrosis, scleroderma and COPD (lung); and acute and chronic nephropathy (kidney).
Utilizing this novel approach, Promedior is initially developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease (eye); pulmonary fibrosis, scleroderma and COPD (lung); and acute and chronic nephropathy (kidney).

Full browser ?